Because of the promising efficacy of the AXL inhibitor in preclinical studies, a clinical trial (NCT03255083) is investigating the safety and tolerability of DS-1205c (an orally administered AXL inhibitor) combined with osimertinib among EGFR-mutated advanced NSCLC subjects. Here, AXL is linked to non-small cell lung carcinoma.